Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tauns LaboratoriesTSE:197A +1.67%15 Return-on-Tangible-Asset is 18.01% as of Dec. 2025, which is 27% below its 10-year median of 24.74. GuruFocus rates TSE:197A with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Tauns Laboratories ranks better than 68.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tauns Laboratories's annualizedNet Income for the quarter that ended in Dec. 2025 was 円6,811 Mil. Tauns Laboratories's average total tangible assets for the quarter that ended in Dec. 2025 was 円37,825 Mil. Therefore, Tauns Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 18.01%.
The historical rank and industry rank for Tauns Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
TSE:197A'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.88 Med: 24.74 Max: 28.9
Current: 5.88
During the past 4 years, Tauns Laboratories's highest Return-on-Tangible-Asset was 28.90%. The lowest was 5.88%. And the median was 24.74%.
TSE:197A's Return-on-Tangible-Asset is ranked better than 68.7% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs TSE:197A: 5.88
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Tauns Laboratories Return-on-Tangible-Asset Related Terms
Tauns Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Tauns Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:197A vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tauns Laboratories Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Tauns Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 18.01% mean?
Tauns Laboratories (TSE:197A) has a Return-on-Tangible-Asset of 18.01% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tauns Laboratories and its competitors. This is 27% below median its historical median of 24.74. Over the past decade, Tauns Laboratories' Return-on-Tangible-Asset has ranged from 5.88 to 28.90. According to the industry distribution chart, Tauns Laboratories ranks #267 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is Tauns Laboratories' Return-on-Tangible-Asset too high?
Tauns Laboratories' current Return-on-Tangible-Asset of 18.01% is 27% below median its 10-year median of 24.74. Over the past 10 years, this metric has ranged from a low of 5.88 to a high of 28.90. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. Tauns Laboratories' value of 18.01% is 2269.7% above this industry median. Based on the distribution chart, Tauns Laboratories ranks #267 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tauns Laboratories has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tauns Laboratories ranks #267 out of 853 companies for Return-on-Tangible-Asset. This puts Tauns Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.76. Tauns Laboratories' value of 18.01% is 2269.7% above this benchmark. Historically, Tauns Laboratories' own Return-on-Tangible-Asset has ranged from 5.88 to 28.90 over the past decade. While the company's 10-year median is 24.74 vs. the industry median of 0.76, Tauns Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tauns Laboratories's current Return-on-Tangible-Asset of 18.01% is 2269.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tauns Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tauns Laboratories's current Return-on-Tangible-Asset is 18.01%, which is 27% below median its own 10-year median of 24.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Return-on-Tangible-Asset of 18.01%. The current Return-on-Tangible-Asset is 18.01%, which is 27% below median its 10-year median of 24.74 and 2269.7% above the Medical Devices & Instruments industry median of 0.76. Tauns Laboratories' overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Return-on-Tangible-Asset is 18.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
15GF Score
Get the complete analysis for TSE:197A
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:197A has been successfully added to your 
